Results 91 to 100 of about 5,546 (214)
New options for the medical treatment of Cushing′s syndrome
Indian Journal of Endocrinology and Metabolism, 2013 A number of drugs have been advocated for the medical management of Cushing′s syndrome but few have gained widespread acceptance. The most reliably effective agents are metyrapone and ketoconazole as monotherapy, or in combination.
Peter J Trainer
doaj +1 more source
Immunity, Inflammation and Disease, Volume 12, Issue 12, December 2024.ABSTRACT Background The overwhelming majority of pituitary tumors consist of pituitary adenomas (PAs), which have recently also been termed pituitary neuroendocrine tumors (PitNETs). Clinically significant PAs occur in approximately one in every 1000 individuals, while other types of pituitary tumors, such as craniopharyngiomas and pituicytomas, are ...
Dingkai Xu, Ling Wang, Maohua Zheng
wiley +1 more source
Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
Frontiers in Endocrinology, 2020 Acromegaly is a disease due to chronic GH excess and a consequent rise in IGF-1 levels. This rare endocrine condition is associated with metabolic alterations such as hyperglycaemia, dyslipidaemia, and systemic arterial hypertension, which, in addition ...
Soraya Puglisi +9 more
doaj +1 more source
Combinatorial drug discovery in nanoliter droplets [PDF]
, 2019 Combinatorial drug treatment strategies perturb biological networks synergistically to achieve therapeutic effects and represent major opportunities to develop advanced treatments across a variety of human disease areas.
Blainey, Paul C +4 more
core +1 more source
E-cadherin expression is associated with somatostatin analogue response in acromegaly [PDF]
, 2018 Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin‐like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity. Somatostatin analogues (SSAs)
Cano, David A. +10 more
core +1 more source
Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation [PDF]
, 2021 Maria Stelmachowska‐Banaś +3 more
openalex +1 more source
Pasireotide: a novel treatment for patients with acromegaly
Drug Design, Development and Therapy, 2016 Daniel Cuevas-Ramos,1 Maria Fleseriu2,3 1Department of Endocrinology and Metabolism, Neuroendocrinology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; 2Department of Medicine ...
Cuevas-Ramos D, Fleseriu M
doaj
, 2012 Cushing’s disease, or pituitary ACTH dependent Cushing’s syndrome, is a rare disease responsible for increased morbidity and mortality. Signs and symptoms of hypercortisolism are usually non specific: obesity, signs of protein wasting, increased blood ...
Bernard Conte-Devolx +3 more
core +1 more source
Tumor-associated stromal cells as key contributors to the tumor microenvironment. [PDF]
, 2016 The tumor microenvironment is a heterogeneous population of cells consisting of the tumor bulk plus supporting cells. It is becoming increasingly evident that these supporting cells are recruited by cancer cells from nearby endogenous host stroma and ...
Bussard, Karen M. +4 more
core +2 more sources
Pasireotide for the prevention of postoperative pancreatic fistula: an open debate [PDF]
, 2019 Maurizio Zizzo +4 more
openalex +1 more source